To Become a Long-Term Partner
for Global Innovative Biotech Companies
Established in 2008, Viva Biotech Holdings (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing to global biopharmaceutical innovators.
Leveraging our leading edge in AI-driven structure-based drug discovery (SBDD), the Company provides CRO services covering the drug discovery stage to global partners. Through the synergistic development of its biology and chemistry capabilities, the Company has established an integrated R&D platform spanning multiple drug modalities, including small molecules, large molecules/antibodies, peptides, PROTACs/molecular glues, and XDCs. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC/CDMO solution from preclinical to commercial manufacturing. Additionally, we embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.
-
2,904Biotech and pharmaceutical clients worldwide -
2,213Employees worldwide -
93Invested and incubated companies
cro
Drug R&D Services
With its leading position in Structure-Based Drug Discovery (SBDD), Viva provides state-of-the-art drug research and development services to global biotechnology and pharmaceutical customers for their preclinical, innovative drug discovery programs. We cover the all-around needs of our clients for their early drug research and development, including protein expression, purification and structure determination, hits screening, therapeutic antibody discovery, antibody expression and production, Bioassay, computer-aided drug design, medicinal chemistry and custom synthesis, ADME, and PK studies.
cdmo
R&D and Production Services
As the subsidiary of Viva Biotech holdings, Langhua offers our worldwide partners One-Stop CDMO solution in new drug full life-cycle for small molecule Active Pharmaceutical Ingredients (APIs) and Finished Dosage Form, from pre-clinical to commercial supply.
Learn more
One-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing
News
Subscribe to Our Newsletter